Tbg Diagnostics Limited (TDL:ASX)


right-arrow Created with Sketch. 0 (0%)
MCAP $58.74M
Last trade 07.10am 13/04/2021 20mins delayed

Latest Announcements

31/03/2021TDLTbg Diagnostics Limited
31/03/2021TDLTbg Diagnostics Limited
31/03/2021TDLTbg Diagnostics Limited
24/03/2021TDLTbg Diagnostics Limited
24/03/2021TDLTbg Diagnostics Limited
23/03/2021TDLTbg Diagnostics Limited
18/03/2021TDLTbg Diagnostics Limited
03/03/2021 Price SensitivePSTDLTbg Diagnostics Limited

Company Overview

TBG Diagnostics Limited, formerly Progen Pharmaceuticals Limited, is a biotechnology company. The Company's principal activities include the discovery, research and development of pharmaceutical therapeutics for the treatment of human diseases, and the provision of contract services related to the process development, manufacture and quality assurance of biopharmaceutical products. The Company's segments include Research & Development, and Manufacturing. The Company is primarily engaged in the discovery and development of small molecule-based cancer therapeutics. The Company is focused on the development of the anti-angiogenesis and anti-metastatic oncology products pipeline. The Company's offerings include Muparfostat (PI-88) and PG545. Muparfostat (PI-88) is an anti-angiogenesis and anti-metastatic compound. Muparfostat (PI-88) is a dual angiogenesis and heparanase inhibitor. PG545 is an agent designed to target the tumor microenvironment.

TDL in the news

Search Previous Announcements